Open AccessThis article is
- freely available
MMP-7 and fcDNA Serum Levels in Early NSCLC and Idiopathic Interstitial Pneumonia: Preliminary Study
Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy
Pulmonology, Department of Thoracic Diseases, Morgagni-Pierantoni Hospital, Forlì 47121, Italy
Unit of Biostatistics and Clinical Trials, IRST IRCCS, Meldola 47014, Italy
Thoracic Surgery, Department of Thoracic Diseases, Morgagni-Pierantoni Hospital, Forlì 47121, Italy
These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 16 September 2013; in revised form: 21 November 2013 / Accepted: 22 November 2013 / Published: 11 December 2013
Abstract: A non-invasive test to facilitate the diagnosis of non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis (IPF) is still not available and represents an important goal. Forty-eight patients with stage I NSCLC, 45 with IPF, 30 with other idiopathic interstitial pneumonias (IIPs) including idiopathic non-specific interstitial pneumonia (NSIP) and chronic hypersensitivity pneumonitis (HP), 35 with diffuse non-malignant disease and 30 healthy donors were enrolled onto the study. Free circulating (fc)DNA and MMP-7 levels were evaluated by Real Time PCR and ELISA, respectively. Median fcDNA levels were similar in NSCLC (127 ng/mL, range 23.6–345 ng/mL) and IPF (106 ng/mL, range 22–224 ng/mL) patients, and significantly lower in IIPs patients, in individuals with other diseases and in healthy donors (p < 0.05). Conversely, median MMP-7 values were significantly higher in IPF patients (9.10 ng/mL, range 3.88–19.72 ng/mL) than in those with NSCLC (6.31 ng/mL, range 3.38–16.36 ng/mL; p < 0.0001), NSIP (6.50 ng/mL, range 1.50–22.47 ng/mL; p = 0.007), other diseases (5.41 ng/mL, range 1.78–15.91, p < 0.0001) or healthy donors (4.35 ng/mL, range 2.45–7.23; p < 0.0001). Serum MMP-7 levels seem to be capable of distinguishing IPF patients from those with any other lung disease. fcDNA levels were similar in NSCLC and IPF patients, confirming its potential role as a biomarker, albeit non-specific, for the differential diagnosis of NSCLC.
Keywords: MMP-7; fcDNA; IPF; NSIP; NSCLC; serum; IIPs
Citations to this Article
Cite This Article
MDPI and ACS Style
Ulivi, P.; Casoni, G.L.; Foschi, G.; Scarpi, E.; Tomassetti, S.; Romagnoli, M.; Ravaglia, C.; Mengozzi, M.; Zoli, W.; Poletti, V. MMP-7 and fcDNA Serum Levels in Early NSCLC and Idiopathic Interstitial Pneumonia: Preliminary Study. Int. J. Mol. Sci. 2013, 14, 24097-24112.
Ulivi P, Casoni GL, Foschi G, Scarpi E, Tomassetti S, Romagnoli M, Ravaglia C, Mengozzi M, Zoli W, Poletti V. MMP-7 and fcDNA Serum Levels in Early NSCLC and Idiopathic Interstitial Pneumonia: Preliminary Study. International Journal of Molecular Sciences. 2013; 14(12):24097-24112.
Ulivi, Paola; Casoni, Gian L.; Foschi, Giovanni; Scarpi, Emanuela; Tomassetti, Sara; Romagnoli, Micaela; Ravaglia, Claudia; Mengozzi, Marta; Zoli, Wainer; Poletti, Venerino. 2013. "MMP-7 and fcDNA Serum Levels in Early NSCLC and Idiopathic Interstitial Pneumonia: Preliminary Study." Int. J. Mol. Sci. 14, no. 12: 24097-24112.